Nepsis Inc. Boosts Bristol Myers Squibb Stake by 50%

Investment firm adds 90,852 shares of the biopharmaceutical company in Q4

Mar. 28, 2026 at 11:13am

Got story updates? Submit your updates here. ›

Nepsis Inc. increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 49.6% during the fourth quarter, according to a recent SEC filing. The investment firm now owns 274,149 shares of the biopharmaceutical company's stock, making it the 11th largest position in Nepsis's portfolio.

Why it matters

Bristol Myers Squibb is a major pharmaceutical company focused on developing treatments for cancer, immune-mediated diseases, and other serious conditions. Nepsis's significant stake and increased investment in the company signals confidence in BMS's pipeline and future growth prospects.

The details

Nepsis Inc. purchased an additional 90,852 shares of Bristol Myers Squibb in the fourth quarter, bringing its total holdings to 274,149 shares. This represents a 49.6% increase from the previous quarter. Bristol Myers Squibb now makes up 4.6% of Nepsis's total investment portfolio, making it the firm's 11th largest position.

  • Nepsis Inc. filed its Q4 2025 13F report with the SEC on March 28, 2026.
  • The additional 90,852 shares were purchased by Nepsis during the fourth quarter of 2025.

The players

Nepsis Inc.

An investment management firm that owns a significant stake in Bristol Myers Squibb.

Bristol Myers Squibb Company

A major biopharmaceutical company focused on developing treatments for cancer, immune-mediated diseases, and other serious conditions.

Got photos? Submit your photos here. ›

The takeaway

Nepsis's increased investment in Bristol Myers Squibb suggests the firm sees strong growth potential in the biopharmaceutical company's product pipeline and future business prospects.